As Chinese assets have become key collaboration targets for global pharmaceutical companies, and as Chinese innovative drugs have grown into important "leaders" in the global pharmaceutical market, there is an urgent need to establish a high-end conference platform in China that is regular, international, and market-oriented. Such a platform would systematically showcase the strengths of Chinese innovative drugs, facilitate connections with multinational pharmaceutical companies and overseas investment institutions, lead the formulation of global rules, and drive the upgrading of the innovation ecosystem.

From July 22 to 24, 2026, the 1st China Pharmaceutical Innovation Conference (CPIC), hosted by TONACEA, will be held at the Golden Hall of the National Exhibition and Convention Center (Shanghai). The conference will feature over 50 thematic events and corporate satellite sessions, bringing together thousands of global industry leaders in Shanghai Hongqiao. Through more than 300 hot topics, participants will focus on the core logic behind the rise of Chinese innovative drugs, explore globalization strategies for innovative pharmaceuticals, and establish a new paradigm of "Chinese Innovation – Global Translation – Shanghai Transaction."

On the occasion of this premier industry event, the inaugural CNS Innovative Drug R&D Conference will be held as the flagship featured conference. Co-hosted by TONACEA, Hanshu Bio, and Quark Pharma, the conference focuses on the high-value, high-potential sector of CNS drug development. It brings together top R&D experts from around the world to decode emerging CNS targets and mechanisms, clinical development, gene editing, and other key technologies. In-depth discussions will cover cutting-edge topics such as CNS disease treatment and global registration strategies for innovative drugs, aiming to establish a professional exchange platform for R&D innovation, clinical translation, industrial collaboration, and global partnership in the CNS field.

We sincerely invite you to join us in Shanghai, where you will gather with colleagues from the pharmaceutical industry at home and abroad to discuss innovation, co-build the ecosystem, and pursue shared development. Together, at this grand event celebrating Chinese pharmaceutical innovation, let us embark on a new chapter of global collaboration in the health industry!

Breakthroughs in CNS Innovation Through Global Collaboration

Global CNS Drug R&D Landscape and China's Opportunities

Frontier Technology Platforms Reshaping the Logic of CNS R&D

Advances in Innovative R&D for Key Indications

Convergence of AI and Brain Science Empowering R&D

Global Exploration and Breakthroughs in Orphan CNS Disease Drug Development

Interpretation of New CNS-Related Policies and Their Impact on the Industry

Investment Logic and Strategies in Frontier CNS R&D from a Capital Perspective

Addressing Key Challenges in Non-Clinical CNS Drug Research

Non-Clinical Evaluation and Optimization Strategies for Brain Delivery Systems

Standards for Non-Clinical Pharmacodynamics and Toxicology Studies

Selection of Models and Biomarkers in CNS Drug Development

Key Considerations in Non-Clinical Study Design

Establishing Quality Systems for Non-Clinical CNS Research

Strategies for Optimizing Clinical Trial Design in CNS Drug Development

Precision Application of Biomarkers in CNS Clinical Development

Key Considerations for Clinical Compliance and Regulatory Submission of CNS Drugs

Addressing Key Challenges and Optimizing Pathways for CNS Clinical Validation

Differentiated Clinical Development Strategies for CNS Drugs Across Indications

Proposed Guest List

Chen Jinhui: Founder & CEO, Glia Pharmaceuticals
Fang Qun: Chief Scientific Officer, Yisi Bio; Head, Brain Science Innovation R&D Center
Gao Shan: CSO & Senior Vice President, Ribobio
Guo Fei: Scientific Advisor, Hanshu Bio
Lai Caida: Co-Founder & CEO, Metis Pharmaceuticals
Li Xiang: Founder & CEO, Shize Biotechnology
Li Huafang: Executive Director, SMHC National Drug Clinical Trial Institution; Director, Shanghai Clinical Research Center for Mental and Psychological Disorders
Liang Congxin: Founder, Chairman & CEO, HighLight Pharmaceuticals
Ren Feng: Co-CEO & CSO, Insilico Medicine
Luan Ping: Principal Investigator, Shenzhen University Health Science Center; Director & Distinguished Professor, National Advanced Cognitive Impairment Diagnosis and Treatment Center (Guangdong Second Provincial General Hospital); Director, Alzheimer's Disease Clinical Research Center, Guangdong Second Provincial General Hospital
Na De: Researcher, Institute of Brain Science, Fudan University
Pan Feng: Vice President of R&D, Simcere Pharmaceutical
Shen Huaqiong (Joan Shen): Founder & CEO, NeuShen Therapeutics
Shen Jingshan: Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Founder, Wangshan Wangshui Biopharmaceuticals
Sheng Xijun: Deputy Dean, R&D Institute, Renfu Pharmaceutical
Tang Qiusong: Head, Roche Accelerator China
Tian Jingwei: Executive Vice President of R&D, Luye Pharma Group; Dean, School of Pharmacy, Yantai University
Xie Xin: Executive Director & Senior Vice President, Sino Biopharmaceutical
Yan Yi: CEO, Pumaisheng Pharmaceuticals
Yu Jintai: Deputy Dean, Institute of Science and Technology, Fudan University; Deputy Director, Department of Neurology, Huashan Hospital Affiliated with Fudan University
Yang Shibao: Founder, Chairman, Executive Director & CEO, Ningdan New Drug
Wang Yutian: Professor, Fudan University Institute for Translational Neuroscience; Fellow of the Royal Society of Canada
Yuan Dawei: Founder, Chairman & General Manager, Beijing Quark Pharma Group
Zhao Xiaoping: CEO, Tzevaot Biopharmaceuticals

More speakers to be announced...